‘Global Radiopharmaceutical Market Worth Over $5 Billion In 2017’ Says Visiongain Report

16 August 2017
Pharma

Visiongain’s new report The Global Radiopharmaceutical Market Forecast 2017-2027: Revenue Prospects by Application (Oncology, Cardiology, Gastroenterology, Neuroendocrinology, Neurology, Nephrology, Others) Radioisotope (Tc-99, F-18, I-131, Lu-177, Y-90, Ga-68, Ga-67, Rb-82, I-123, I-125, I-111, Others), Source (Cyclotrons, Nuclear Reactors), End User (Hospitals, Diagnostic Imaging Centres, Ambulatory Surgical Centres, Cancer Research Institutes) and Geography indicates that the global Radiopharmaceutical market will see over $5bn in revenue in 2017.
The lead analyst of the report said:

“The market for radiopharmaceuticals is mainly driven by factors such as growth in R&D investments made in the biotechnology and pharmaceutical sector, technological advancements in nuclear medicine, the increasing burden of cancer and the ageing global population. The application of radiopharmaceuticals in diverse range of medical conditions will provide new growth opportunities to key players in the radiopharmaceutical market.

The competitive landscape of the global biosimulation market experiences intense competition to expand their share across globe. The Key players in the global biosimulation market include Siemens AG, Eckert & Ziegler, Lantheus Medical Imaging, Cardinal Health, Inc. and Bayer AG.
Technological advancements coupled with focus of key players focused on emerging nations to capitalize on their potential is expected to propel the growth of the global radiopharmaceutical market during the forecast period.”

The 234-page report contains 193 tables, charts and graphs that add visual analysis in order to explain developing trends within the Radiopharmaceutical market. Visiongain provides revenue forecasts for the period 2017-2027 for the leading Radiopharmaceutical submarkets. The market for radiopharmaceuticals is segmented based on application, radioisotope, source, end-user, and by geography. Based on application, the radiopharmaceutical market is segmented into Oncology, Cardiology, Gastroenterology, Neuroendocrinology, Neurology, Nephrology and Others. Based on radioisotope, the radiopharmaceutical market is segmented into Tc-99, F-18, I-131, Lu-177, Y-90, Ga-68, Ga-67, Rb-82, I-123, I-125, I-111 and others. The radiopharmaceutical market by source market is segmented into cyclotrons and nuclear reactors. Based on the end-user the market is categorized into hospitals, diagnostic imaging centres, ambulatory surgical centres and cancer research institutes. The geographical breakdown includes analysis of North America, Latin America. Western Europe, Eastern Europe, Asia-Pacific, and MEA.

The 234-page report offers market forecasts and analysis for 6 regional and 21 key national markets. In addition, the report contains a dedicated leading companies’ chapter covering
9 companies leading the Radiopharmaceutical field in detail.

The Global Radiopharmaceutical Market Forecast 2017-2027: Revenue Prospects by Application (Oncology, Cardiology, Gastroenterology, Neuroendocrinology, Neurology, Nephrology, Others) Radioisotope (Tc-99, F-18, I-131, Lu-177, Y-90, Ga-68, Ga-67, Rb-82, I-123, I-125, I-111, Others), Source (Cyclotrons, Nuclear Reactors), End User (Hospitals, Diagnostic Imaging Centres, Ambulatory Surgical Centres, Cancer Research Institutes) and Geography report will be of value to anyone who wants to better understand the radiopharmaceutical market and its various segments. It will be useful for businesses who wish to better comprehend the part of the market they are already involved in, or those wishing to enter or expand into a different regional or technical part of the radiopharmaceutical industry.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44 (0) 207 336 6100

About visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-to-business conferences, newsletters, management reports and e-zines focusing on the automotive, chemical, cyber, defence, energy, pharmaceutical, materials and telecoms sectors.

Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Biological API Manufacturing Services Market Report 2021-2031

Demand in the early years of the forecast period will come from multinational biotech looking to sign deals with Indian companies and take advantage of the cheaper costs of production for the emerging market.

08 January 2021

Read

Visiongain Publishes Anaesthesia & Respiratory Devices Market Report 2020-2030

The growth can be attributed to the rising prevalence of respiratory diseases, growing awareness for respiratory diseases, and innovations in respiratory and anesthesia devices. However, unfavourable reimbursement policies and lack of patient adherence in respiratory diseases are some of the factors restraining the growth of the anesthesia and respiratory devices market.

07 January 2021

Read

Visiongain Publishes Inactivated Vaccines Market Report 2020-2030

Factors such as rise in the prevalence of the infectious and bacterial diseases and active participation of government in vaccine development are driving the growth of this market. While high cost of vaccine development is the key factor emerging as a growth barrier over years in this market.

07 January 2021

Read

Visiongain Publishes Human Microbiome Therapeutics Market Report 2021-2031

The potential of microbiome-based drugs as novel treatments to address the unmet needs for many diseases has contributed intensively to the rapid emergence of many investors in this area. Currently, no regulatory framework exists and no drugs have received FDA approval. However, there are several preclinical and clinical-stage companies working with various approaches to develop microbiome-based therapies.

06 January 2021

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever